Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).
All entries for: Karyopharm Therapeutics
November 3, 2025
Karyopharm Therapeutics
Neutral Outlook
Newton, MA
201-500 employees
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
July 14, 2025
Karyopharm Therapeutics
Layoffs
Newton, MA
201-500 employees
As it continues exploring options to extend its cash runway, which could include a merger or sale, Karyopharm Therapeutics is cutting about 20% of its workforce, according to a July 11 SEC filing. The Newton, Massachusetts–based commercial-stage pharma did not specify which locations the layoffs affect.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule